Low-dosed docetaxel showed equivalent efficacy but improved tolerability compared with oxaliplatin in the S-1-based first-line chemotherapy regimen for metastatic or recurrent gastric adenocarcinoma.

@article{Guo2015LowdosedDS,
  title={Low-dosed docetaxel showed equivalent efficacy but improved tolerability compared with oxaliplatin in the S-1-based first-line chemotherapy regimen for metastatic or recurrent gastric adenocarcinoma.},
  author={Mengzhou Guo and Yiyi Yu and Yanli Wang and Yuehong Cui and Qian Li and Yi Feng and Wei Li and Rongyuan Zhuang and Tianshu Liu},
  journal={Medical oncology},
  year={2015},
  volume={32 9},
  pages={
          230
        }
}
Platinum-fluoropyrimidine combinations are the preferred first-line options for advanced gastric cancer (AGC) in East Asia. On the other hand, docetaxel-containing regimens without platinum have demonstrated promising activity in AGC. However, dose-related toxicity of docetaxel has limited its clinical adoption. This study compared the efficacy and safety of a modified low-dosed docetaxel plus S-1 (mDS) with oxaliplatin plus S-1 (SOX) in Chinese patients with AGC. Patients were assigned to… CONTINUE READING